IASR J. Med. Pharm. Sci.
ISSN: 2582-9343
Website: https://ijmps.com/
Open Access Journal
Country: India

IASR Journal of
Medical and
Pharmaceutical Science

REVIEW ARTICLE OPEN ACCESS

RECENT TRENDS AND CHALLENGES IN DRUG DESIGN: A REVIEW

Navneet Kumar Verma*[1], Keshav Kumar Gupta[2]

Associate Professor, Suyash Institute of Pharmacy, Hakkabad, Gorakhpur, UP, India-2730161,
Professor, Buddha Institute of Pharmacy, GIDA, Gorakhpur, UP, India-2732092. Email – Navneet_its04@rediffmail.com

OPEN ACCESS

Navneet Kumar Verma
Associate Professor, Suyash Institute of Pharmacy, Hakkabad, Gorakhpur, UP, India-2730161

Received: 15-09-2025
Accepted: 24-10-2025
Available online: 09-11-2025

ABSTRACT

Drug design, or ligand-based drug molecular design of new molecules to interact with a biological target for effective regulation of its activity has been an indispensable and ever-evolving discipline in pharmaceutical research. The addition of newer technologies like Computational Aided Drug Design (CADD) has enriched this process by using computational tools to screen and refine drug candidates, hence empowering for an easy parallel implementation which ultimately shortens the timeline and financial involvement in designing drugs. Artificial Intelligence (AI) and its subset Machine Learning (ML), have become increasingly prominent in recent years to facilitate better virtual screening, molecular docking, and predictive modeling which are crucial for the detection of novel therapies especially regarding the diseases with complex etiology like cancer. Nanotechnology-assisted targeted drug delivery systems have been successfully applied to the field, enabling site-specific release of drugs and reducing their side effects while improving therapeutic efficacy. Likewise, the advent of biologics, biosimilars and multitarget drug design has brought new directions to tackle diseases that have evolved from their relatively simple causative pathways.

Keywords; Drug design; Ligand-based drug design; Computational Aided Drug Design (CADD); Artificial Intelligence (AI)

Introduction

Drug design is a process aimed at creating works of manpower in new molecules, brought into life only by their interaction with biological targets to adjust their activeness. It is essential in creating new medications that will be able to cure a lot of diseases .Drug design, otherwise referred to as rational drug design, is simply a process for creating new molecules that would interact with certain biological targets, modulating their activity either by inhibition or enhancement for therapeutic purposes [1] [2]. This, therefore, implies knowledge of how molecules bind to cell receptors or other molecules to elicit some response with a view to coming up with effective and safe pharmaceutical products [3]. CADD is an important companion in this process, as it makes use of computer techniques on huge biological databases to identify possible drug candidates and reduces the chances of late failures [1]. These strategies of drug design also address the barriers of drug delivery by linking drugs to polymers or antibodies in order to enhance targeting and stability, thus improving their efficacy and bioavailability [4]. The current evolution of drug design was fashioned by the development of high throughput sequencing, proteomics, metabolomics, and in silico drug development. All these make up the complex yet imperative areas of modern pharmaceutical research [1,3].

Recent Trends In Drug Design:

Computer-Aided Drug Designing (CADD) tools came into existence and helped make the process more efficient, thus reducing the costs and time required for drug discovery through approaches such as Structure-Based Drug Designing (SBDD) and Ligand-Based Drug Designing (LBDD)[5]. The integration of informatics with pharmaceutical sciences led to the emergence of Computer-Aided Drug Design (CADD), thus enhancing Rational Drug Design(RDD) through molecular modeling and simulations[6]. Being an advance trend in Drug design, this brings together latest technologies and new methodoligies to make pharma R&D more efficient. Among them, artificial intelligence has been a major factor in drug discovery; it uses virtual screening, de novo molecule design and toxicity prediction [7].Through these

methodologies and others, computational drug design techniques, such as computer-aided drug design, molecular docking, and molecular dynamics simulations, have become indispensable in identifying new therapies, particularly in cancer research [8]. Advanced systems of drug delivery, based on nanoparticles, liposome, and micro needles, have therefore permitted a strict time and site control of the release of a medicament, making the medication administration much more effective and side effect-free[9]. Cargo-based, such as liposomes and nanoemulsions, seem to be one of the most promising approaches in the formulations developed against atopic dermatitis [10]. These trends reflect a change in the current collaborations between disciplines and the implementation of AI-driven approaches to move drug discovery towards a new era of innovation and efficacy.

Challenges In Drug Design

Some of the challenges include dealing with the accuracy and computational cost trade-off in quantum mechanics[11], complexity faced by computer-aided drug design scientists despite having access to experimental structures for their targets [12], supramolecular factor as a consideration when designing agents against drug-resistant fungi and bacteria[13], increasing need to employ Deep Learning in pharmaceutical research, development practices especially during companion work involved in improved Drug Discovery [27] or modelling native structure & ligand-binding behavior associated problems about translocator protein 18 kDa(TSPO)[14]. This showcases the multi-faceted form of drug designing, highlighting challenges that stand in our way and corresponding efforts being made to surmount these barriers which will help push forward new lines of proceses : more effective and efficient drugs discovery pipelines. Drug resistance and pathogen evolution are two critical issues in pharmaceutical research; consequently, there is a lot of interest among developmental biologists to address them the examination relating areas. To combat these challenges, many computational methodologies like quantum mechanics (QM) methods[11] artificial intelligence (AI), specifically machine learning(ML)/deep learning(DL)[27] and computer-aided drug design(CADD)[14] techniques have been utilized. They are intended to improve molecule screening, increase drug discovery power and compensate for deficiencies in the modeling of protein structures including those that pertain ligand-binding behavior specifically seen withthe translocator protein 18 kDa (TSPO) [15]. Using advanced computational methods and coupling AI with quantum mechanics, researchers are striving to develop promising strategies in tackling drug resistance phenotypes and evolutionary insights into the pathogens so this would eventually allow for the identification of new therapeutic agents which will be potent. One of the biggest challenges in drug design is reducing toxicity, side effects that result as additional complications and arise when drugs affect general metabolism pathways leading to reduced potential for new medications. The supramolecular facet, underrepresented in drug breakthrough segments regarding selectivity of medication applicants, has an essential position– including some situations where selective monomers display better pickiness than aggregated forms [16]. Moreover, human biology is so complex that designing drug molecules with a desired specificity and suitable pharmacokinetic profile becomes an aggressive act without side effects [17]. New drug compounds are now being designed using cheminformatics and machine learning techniques in a more efficient way that leverages these advanced chemical descriptors to expedite compound selection with reduced toxicity risks [18]. Tackling this challenge will need an integrated, multidisciplinary effort of computational methods overlaid with structural-based drug design combined with a comprehensive understanding of biological target to discovery safe and potent therapeutics.

Future Scope And Innovations

There is much greater scope for drug design in the future, fueled by state-of-art technologies such as Artificial Intelligence and Nanotechnology along with advanced Drug Delivery systems. The incorporation of AI into drug design has disrupted the field and facilitated effective virtual screening, de novo ligand synthesis as well as predict toxicologically effects [9,7]. Utilization of Nanotechnology for Drug delivery some definition Nanotherapeutics (Multifunctional) and nanorobots, 3D printing applications in drug administrations; leading to new approaches on personalized medicine, propose innovative therapeutics against diseases such as cancer [19].Moreover, evolution of targeted cancer therapies like antibody-drug conjugates (ADCs) has tailor-made next-generation ADC to have better therapeutic index resulting in improved clinical outcomes for patients [9, 20]. This confluence of technologies will define the future for drug design effacious drugs, personalized treatments and patient centricity to improve human diseases. In the coming years, there are going to be some major improvements in drug design owing to the integration of Computer-aided Drug Design (CADD), prodrugs and virtual screening technologies. These technologies have grown rapidly with Machine Learning and Artificial Intelligence being integrated rapidly into the CADD systems and hence becoming quite instrumental in rationalizing drug discovery processes while also enhancing their predictive capabilities [21]. Special drugs also referred to as prodrugs can provide personalized therapeutic solutions through special delivery systems which allow for controlling the rate at which the active ingredient is released into circulation leading to personalized medicine [21]. Moreover, virtual screening technology has become an inexpensive yet effective way of enhancing new antiviral drug development especially when dealing with dangerous viruses that change so fast like COVID-19 [21]. The limelight is on these new methods of drug discovery that will optimize algorithms, tackle ethical issues and support sustainability measures for a healthier and more resilient future regarding pharmaceutical interventions.

Conclusion

Advanced technologies, more so CADD, AI, and nanotechnology, have bundled to make a very huge impact on the evolution of drug design. The innovations that have altered the pharmaceutical landscape not only accelerate the discovery process of drugs but also enhance their precision and efficacy in therapeutic interventions. Targeted drug delivery systems, as most recently developed, offer very bright prospects for treating complex diseases, beside the development of biologics, biosimilars, and multitarget approaches. Certainly, however, despite all the successes of these developments, resistance to medicaments, their toxicity, and problems with computational models remain serious hurdles. Further interdisciplinary efforts will be required to channel the strength of AI, molecular modeling, and other emerging technologies in refinement and innovations in drug development processes.

References

1. Siddharth, Yadav., Ashutosh, Bhardwaj., Puniti, Mathur. (2024). Databases in Drug Design. 185-200. doi: 10.1201/9781003455424-10

2.Tanuja, Nimbalkar, -., Trupti, Shelar, -., Mohammed, Azim, Naikwadi, -. (2023). A Review on Drug Design and Development. International Journal For Multidisciplinary Research, 5(4) doi: 10.36948/ijfmr.2023.v05i04.5589

3. Paweł, Mehring. (2023). Drug Design. 182-192. doi: 10.1016/b978-0-12-821618-7.00071-7

4.Jun, Xu. (2022). Evolving Drug Design Methodology: from QSAR to AIDD. doi: 10.26434/chemrxiv-2022-9fwmg

5.Navneet, Kaur., Mymoona, Akhter., C., M., Singla. (2022). Drug designing: Lifeline for the drug discovery and development process. Research Journal of Chemistry and Environment, 26(8):173-179. doi: 10.25303/2608rjce1730179

6.T., Durai, Ananda, Kumar. (2022). Drug Design: A Conceptual Overview. doi: 10.1201/9781003298755

7.Ram, Babu, Sharma., S., Kaushal., Amardeep, Kaur., Divya, Dhawal, Bhndari. (2024). Artificial intelligence: recent advancementsin drug design and development. 118-130. doi: 10.58532/v3bgpn19p1ch11

8.Iashia, Tur, Razia., Ayesha, Kanwal., Hafiza, Fatima, Riaz., Abbeha, Malik., Muhammad, Ahsan., Muhammad, Saleem, Khan., Ali, Raza., Sumera, Sabir., Zureesha, Sajid., Muhammad, Fardeen, Khan., Rana, Adnan, Tahir., Sheikh, Arslan, Sehgal. (2023). Recent Trends in Computer-aided Drug Design for Anti-cancer Drug Discovery.. Current Topics in Medicinal Chemistry, doi: 10.2174/0115680266258467231107102643

9.Ram, Narayan, Prajapati., Bharat, Bhushan., Kuldeep, Singh., Himansu, Chopra., Shivendra, Kumar., M., C., Agrawal., Devender, Pathak., Dilip, Kumar, Chanchal., LAXMI, KANT. (2024). Recent Advances in Pharmaceutical Design: Unleashing the Potential of Novel Therapeutics. Current Pharmaceutical Biotechnology, 25 doi: 10.2174/0113892010275850240102105033

10.Amisha., Dilpreet, K., Singh., Balak, Das, Kurmi. (2023). Recent Advances in Nanocarrier-based Approaches to Atopic Dermatitis and Emerging Trends in Drug Development and Design.. Current Drug Delivery, 20 doi: 10.2174/1567201820666230508121716

11. Tiziana, Ginex., Carolina, Estarellas., Javier, Vázquez., Carolina, Estarellas. (2024). Quantum mechanical-based strategies in drug discovery: Finding the pace to new challenges in drug design. Current Opinion in Structural Biology, 87:102870-102870. doi: 10.1016/j.sbi.2024.102870

12. Daniele, Pala., David, E., Clark. (2024). Caught between a ROCK and a hard place: current challenges in structure-based drug design. Drug Discovery Today, 104106-104106. doi: 10.1016/j.drudis.2024.104106

13. Steven, L., Regen. (2024). Drug Design: Do Not Forget the Supramolecular Factor.. Biochemistry, doi: 10.1021/acs.biochem.3c00721

14. Limitations and future challenges of computer-aided drug design methods. (2022). 283-297. doi: 10.1016/b978-0-323-90608-1.00006-x

15. Mia, Giladi., Andrew, P., Montgomery., Michael, Kassiou., Jonathan, J, Danon. (2024). Structure-Based Drug Design for TSPO: Challenges and Opportunities.. Biochimie, doi: 10.1016/j.biochi.2024.05.018

16. (2023). New challenges in drug discovery. 619-643. doi: 10.1016/b978-0-323-91376-8.00021-5

17. Essam, H., Houssein., Mosa, E., Hosney., Diego, Oliva., No, Ortega-Sánchez., Waleed, M., Mohamed., Mahmoud, Hassaballah. (2021). Drug Design and Discovery: Theory, Applications, Open Issues and Challenges. 337-358. doi: 10.1007/978-3-030-70542-8_15

18. Laksiri, Weerasinghe., Imalka, Munaweera., NULL, AUTHOR_ID. (2024). Future of Nanotechnology-Based Drug Discovery. 191-207. doi: 10.2174/9789815238815124010008

19. Laurence, Gauzy-Lazo., Ingrid, Sassoon., Marie-Priscille, Brun. (2020). Advances in Antibody–Drug Conjugate Design: Current Clinical Landscape and Future Innovations:. 25(8):843-868. doi: 10.1177/2472555220912955

20. N, L, Swathi., P, Sirisha., S, Preethi., M, Devadarshini., Grandhe, Neelima., Rajasekhar, Sreerama. (2024). An overview of future prospective in prodrugs development. 62-76. doi: 10.58532/v3bapn5ch7

21. Su, Weikang. (2023). Advances in virtual screening techniques for anti-viral drug design: A computational perspective. Theoretical and natural science, 17(1):185-194. doi: 10.54254/2753-8818/17/20240683